用psoralen装载的肠道向的口腔纳米脂酶减轻了DSS诱导的性结肠炎
Liqian Su1, Gaoqing Song1,2,3, Tao Zhou1,2,3
1Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of BasicMedical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China. luxuemei605@163.com.
Biomaterials science
|May 17, 2024
概括
研究人员开发了新的纳米脂质体 (NLP),封装了psoralen (P),并涂上了奇托 (CH) 和pectin (PT). 这些PT/CH-P-NLPs通过在结肠中释放psoralen来有效治疗性结肠炎,减少炎症和氧化应激.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 口服药物管理面临的挑战是由于复杂的消化环境.
- 松素 (P) 具有治疗潜力,但需要有效的治疗性结肠炎.
- 纳米脂质体 (NLP) 为向药物输送提供了一个有前途的平台.
研究的目的:
- 开发和表征含素的纳米脂质体,涂上素和pectin (PT/CH-P-NLPs) 用于口服.
- 在模拟的消化条件下评估PT/CH-P-NLPs中的psoralen的稳定性和释放特征.
- 评估PT/CH-P-NLPs在性结肠炎小鼠模型中的治疗疗效.
主要方法:
- 使用奇托和点涂层制备带有psoralen的纳米脂质体 (PT/CH-P-NLPs).
- 在不同pH值和酶条件下对纳米脂质体稳定性和psoralen释放的体外评估.
- 在硫酸 (DSS) 诱导的性结肠炎小鼠模型中对PT/CH-P-NLPs的体内评估,评估炎症,氧化应激和肠道微生物群.
- 对PT/CH-P-NLPs与自由psoralen和非涂层脂质体相比进行生物相容性评估.
主要成果:
- PT/CH-P-NLPs表现出良好的生物相容性,优于传统的脂质体和免费的psoralen.
- 纳米脂质体在胃和小肠中保持稳定,在结肠中突发释放psoralen.
- 口服PT/CH-P-NLPs显著降低了炎症,氧化应激,并保护了DSS诱导的性结肠炎小鼠的结肠粘膜屏障.
- 在PT/CH-P-NLP治疗后观察到肠道微生物组合的调节.
结论:
- 设计的PT/CH-P-NLPs提供了稳定有效的psoralen口服输送系统.
- 通过这些纳米脂质体输送的psoralen显示了性结肠炎治疗的显著治疗潜力.
- 这种纳米脂质体配方代表了管理炎症性肠道疾病的有希望的策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
450
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
450


